BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• Press Releases

  Avanzanite Bioscience Appoints Chief Financial Officer

  February 3, 2025

   · 

  3 min read
• Press Releases

  Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions

  February 3, 2025

   · 

  8 min read
• Press Releases

  Dxcover Accelerates Growth With New Funding Round and Strengthens the Leadership Team

  February 3, 2025

   · 

  4 min read
• Press Releases

  AliveDx Expands Autoimmune Menu with IVDR-CE Marked MosaiQ AiPlex® CTDplus Multiplex Assay to Aid in Diagnosing Systemic Autoimmune Rheumatic Diseases and Streamline Laboratory Workflow

  February 3, 2025

   · 

  4 min read
• Press Releases

  Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

  February 3, 2025

   · 

  5 min read
• Press Releases

  uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

  February 3, 2025

   · 

  5 min read
• Press Releases

  Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference

  February 3, 2025

   · 

  1 min read
• Press Releases

  HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

  February 3, 2025

   · 

  7 min read
• Press Releases

  Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025

  February 3, 2025

   · 

  7 min read
• Press Releases

  Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

  February 3, 2025

   · 

  8 min read